An observational study in Ovarian Cancer, sponsored by Vanderbilt-Ingram Cancer Center. Completed. Open to female participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2013-04-18.
Sponsored by Vanderbilt-Ingram Cancer Center · Observational
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future.
PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.
OBJECTIVES:
OUTLINE: This is a pilot study.
Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E_2 metabolite (PGE-M).
Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 7 is below the median of 200 across 527 observational studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Vanderbilt-Ingram Cancer Center is the lead sponsor of 220 studies on the registry; 32 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women with known or suspected ovarian cancer who are greater than 17 years in age.
Exclusion Criteria:
PRIOR CONCURRENT THERAPY:
Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
Genetic: protein expression analysis · Other: immunohistochemistry
protein expression analysis
Also known as: protein expression analysis for PGE-M
immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Also known as: immunohistochemistry staining methods
Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples
Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine.
Time frame: Pre-surgical or chemotherapeutic treatment, over a 24-hour duration
COX-1 and COX-2 expression in ovarian tumor tissue and non-malignant tissue
COX-1 and COX-2 expression will be measured in samples of patients' malignant ovarian samples and matched non-malignant samples (the latter if available).
Time frame: Day of surgery
Correlation of urine PGE-M levels with tissue COX-1 and COX-2 levels
Patients' levels of urine PGE-M will be compared and contrasted with their levels of COX-1 and COX-2 in ovarian tumor tissue
Time frame: After patients' surgery
No study locations are listed for this record.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt-Ingram Cancer Center